Home
/
Lexaria Bioscience Corp.
/
Financials
/
Quarterly
Lexaria Bioscience Corp. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Lexaria Bioscience Corp. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Feb 28, 2026
$20.0K
Apr 13, 2026
Q1
2026
Nov 30, 2025
$0
Jan 13, 2026
Q3
2025
May 31, 2025
$174.0K
Jul 14, 2025
Q2
2026
Feb 28, 2025
$174.0K
Apr 13, 2026
Q1
2026
Nov 30, 2024
$183.9K
Jan 13, 2026
Q3
2025
May 31, 2024
$84.0K
Jul 14, 2025
Q2
2025
Feb 29, 2024
$145.0K
Apr 14, 2025
Q1
2025
Nov 30, 2023
$151.3K
Jan 10, 2025
Q3
2024
May 31, 2023
$77.7K
Jul 12, 2024
Q2
2024
Feb 28, 2023
$20.0K
Apr 9, 2024
Q1
2023
Nov 30, 2022
$97.7K
Jan 12, 2024
Q3
2023
May 31, 2022
$99.7K
Jul 14, 2023
Q2
2023
Feb 28, 2022
$30.7K
Apr 14, 2023
Q1
2023
Nov 30, 2021
$13.9K
Jan 18, 2023
Q3
2022
May 31, 2021
$204.1K
Jul 14, 2022
Q2
2022
Feb 28, 2021
$192.0K
Apr 11, 2022
Q1
2022
Nov 30, 2020
$295.7K
Jan 14, 2022
Q3
2018
May 31, 2018
$140.3K
Jul 13, 2018
Q2
2018
Feb 28, 2018
$172.0K
Apr 12, 2018
Q1
2018
Nov 30, 2017
$24.6K
Jan 12, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2025
Nov 30, 2024
$183.9K
Jan 10, 2025
Q3
2024
May 31, 2024
$380.3K
Jul 12, 2024
Q2
2024
Feb 29, 2024
$296.3K
Apr 9, 2024
Q1
2025
Nov 30, 2023
$151.3K
Jan 10, 2025
Q3
2024
May 31, 2023
$195.5K
Jul 12, 2024
Q2
2024
Feb 28, 2023
$117.8K
Apr 9, 2024
Q1
2023
Nov 30, 2022
$97.7K
Jan 12, 2024
Q3
2023
May 31, 2022
$144.2K
Jul 14, 2023
Q2
2023
Feb 28, 2022
$44.5K
Apr 14, 2023
Q1
2023
Nov 30, 2021
$13.9K
Jan 18, 2023
Q3
2021
May 31, 2021
$204.1K
Jul 15, 2021
Q2
2021
Feb 28, 2021
$192.0K
Apr 14, 2021
Q1
2021
Nov 30, 2020
$295.7K
Jan 14, 2021
Q3
2021
May 31, 2020
$36.4K
Jul 15, 2021
Q2
2021
Feb 29, 2020
$37.5K
Apr 14, 2021
Q1
2021
Nov 30, 2019
$10.3K
Jan 14, 2021
Q3
2020
May 31, 2019
$59.9K
Jun 29, 2020
Q2
2020
Feb 28, 2019
$15.3K
Apr 3, 2020
Q1
2020
Nov 30, 2018
$22.2K
Jan 9, 2020
Q3
2019
May 31, 2018
$140.3K
Jul 8, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Feb 28, 2026
($1.45M)
Apr 13, 2026
Q1
2026
Nov 30, 2025
($1.60M)
Jan 13, 2026
Q3
2025
May 31, 2025
($3.79M)
Jul 14, 2025
Q2
2026
Feb 28, 2025
($2.71M)
Apr 13, 2026
Q3
2025
Feb 28, 2025
($2.71M)
Jul 14, 2025
Q1
2026
Nov 30, 2024
($2.70M)
Jan 13, 2026
Q3
2025
Nov 30, 2024
($2.70M)
Jul 14, 2025
Q2
2025
Nov 30, 2024
($2.70M)
Apr 14, 2025
Q3
2025
May 31, 2024
($1.78M)
Jul 14, 2025
Q2
2025
Feb 29, 2024
($649.5K)
Apr 14, 2025
Q3
2025
Feb 29, 2024
($649.5K)
Jul 14, 2025
Q1
2025
Nov 30, 2023
($1.18M)
Jan 10, 2025
Q2
2025
Nov 30, 2023
($1.18M)
Apr 14, 2025
Q3
2025
Nov 30, 2023
($1.18M)
Jul 14, 2025
Q3
2024
May 31, 2023
($2.37M)
Jul 12, 2024
Q2
2024
Feb 28, 2023
($1.30M)
Apr 9, 2024
Q3
2024
Feb 28, 2023
($1.30M)
Jul 12, 2024
Q3
2024
Nov 30, 2022
($1.76M)
Jul 12, 2024
Q1
2023
Nov 30, 2022
($1.76M)
Jan 12, 2024
Q2
2024
Nov 30, 2022
($1.76M)
Apr 9, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Feb 28, 2026
($1.45M)
Apr 13, 2026
Q1
2026
Nov 30, 2025
($1.57M)
Jan 13, 2026
Q3
2025
May 31, 2025
($3.75M)
Jul 14, 2025
Q2
2026
Feb 28, 2025
($2.75M)
Apr 13, 2026
Q1
2026
Nov 30, 2024
($2.69M)
Jan 13, 2026
Q3
2025
May 31, 2024
($1.74M)
Jul 14, 2025
Q2
2025
Feb 29, 2024
($668.0K)
Apr 14, 2025
Q1
2025
Nov 30, 2023
($1.14M)
Jan 10, 2025
Q3
2024
May 31, 2023
($2.40M)
Jul 12, 2024
Q2
2024
Feb 28, 2023
($1.32M)
Apr 9, 2024
Q1
2023
Nov 30, 2022
($1.70M)
Jan 12, 2024
Q3
2022
May 31, 2022
($2.42M)
Jul 14, 2022
Q3
2022
May 31, 2021
($2.57M)
Jul 14, 2022
Q2
2018
Feb 28, 2018
($1.96M)
Apr 12, 2018
Q1
2018
Nov 30, 2017
($578.7K)
Jan 12, 2018
Q2
2018
Feb 28, 2017
($865.5K)
Apr 12, 2018
Q1
2018
Nov 30, 2016
($400.6K)
Jan 12, 2018
Q3
2016
May 31, 2016
($264.2K)
Jul 13, 2016
Q2
2016
Feb 29, 2016
($274.6K)
Apr 13, 2016
Q1
2016
Nov 30, 2015
($411.7K)
Jan 8, 2016